Viewing data from:

KAITLIB FE

ANDA

ETHINYL ESTRADIOL; NORETHINDRONE | A203448 | LUPIN LTD

1 strength0 unique patents0 unique exclusivities

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
WARNER CHILCOTT COMPANY, LLC v. LUPIN LTD. et al 3:2011cv07228 1 patentANDA 203448norethindrone and ethinyl estradiol	D.N.J.	2011-12-12	Terminated 2014-04-29	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$1.29

per ea

Lowest NADAC/Unit

$1.29

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
68180090373KAITLIB FE 0.8-0.025 MG CHEW TB	$1.29	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

Medicare Part D Spending

CMS annual spending data for Kaitlib Fe (2024)

Total Spending

$28K

Total Claims

243

Beneficiaries

Avg Cost/Unit

$1.83

Spending Trend

$28K(2019)→$31K(2020)→$30K(2021)→$32K(2022)→$27K(2023)→$28K(2024)

YoY Change:-3.9%

5yr CAGR:-7.4%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Products (1)

#001 — 0.025MG;0.8MG

0 patents0 exclusivities▴

TABLET, CHEWABLE;ORAL | Approved: Dec 17, 2015

No patent or exclusivity listings for this strength.